title: Early and intermediate stage Hodgkin's lymphoma--report from the Swedish National Care Programme.
abstract: In Sweden a National Care Programme provides treatment principles for Hodgkin's lymphoma (HL) since 1985, for early and intermediate stages often less extensive than international recommendations. The purpose is to evaluate long-term results of these principles. A total of 308 patients (167 men and 141 women), 17-59 yr old (median 31), diagnosed during 1985-92, pathological stage (PS) I-III1A and I-IIB and clinical stage (CS) I-IIA, mean follow-up 8.8 yr, were studied. Staging laparotomy was recommended in CS IIA. Recommended treatment was mantle or mini-mantle radiotherapy (RT) alone in CS IA, and PS I-IIA and subtotal nodal irradiation in PS III1A if the disease was not bulky. Patients in PS I-IIA and III1A with bulky disease, and PS I-IIB received one cycle of mechlorethamine, vincristine, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, lacarbazine (MOPP/ABVD) before irradiation. The remaining patients received three to four cycles of MOPP/ABVD with RT to bulky disease. Relapse-free (RFS), Hodgkin specific (HLS), and overall survival (OS) at 10 yr were 74%, 92% and 85%. In the individual stages, RFS ranged from 53% (PSIII1A) to 90% (PS IA). RFS (P = 0.006), HLS, and OS were significantly better in patients treated with chemotherapy compared with those treated with RT alone, especially in patients with bulky disease (P = 0.0005). The international prognostic score did not provide any prognostic information. The OS rates are in agreement with results from international centres during that time. The recommended treatment was sufficient to produce the desired results of <20-30% recurrences, except in PS III1A. Most relapses could be salvaged. Patients with risk factors treated with one MOPP/ABVD and RT had an excellent outcome, superior to those without risk factors treated with RT alone. These results favour the trend to treat early and intermediate stages with a short course of chemotherapy followed by limited RT.
authors.affiliation: Department of Oncology, Radiology, and Clinical Immunology, University Hospital, Uppsala, Sweden. daniel.molin@onkologi.uu.se
authors.forename: Daniel
authors.initials: D
authors.lastname: Molin
authors.forename: Gunilla
authors.initials: G
authors.lastname: Enblad
authors.forename: Anita
authors.initials: A
authors.lastname: Gustavsson
authors.forename: Tor
authors.initials: T
authors.lastname: Ekman
authors.forename: Martin
authors.initials: M
authors.lastname: Erlanson
authors.forename: Eva
authors.initials: E
authors.lastname: Haapaniemi
authors.forename: Bengt
authors.initials: B
authors.lastname: Glimelius
mesh_terms: D000293:Adolescent; D000328:Adult; D001483:Base Sequence; D003695:Delivery of Health Care; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009367:Neoplasm Staging; D011379:Prognosis; D012042:Registries; D012307:Risk Factors; D016019:Survival Analysis; D013548:Sweden; D016896:Treatment Outcome